Myc is an oncoprotein transcription factor that promotes cell proliferation and apoptosis. Analysis of highly conserved elements within vertebrate Myc proteins has been instrumental in defining the functions of the Myc protein. Here, we probe the role of a highly conserved, but little studied, element within the central region of c-Myc, termed 'Myc box III' (MbIII). We show that MbIII is important for transcriptional repression by Myc, and for transformation both in vitro and in a mouse model of lymphomagenesis. Curiously, disruption of MbIII decreases transformation activity by increasing the efficiency with which Myc can induce apoptosis, suggesting that MbIII is a negative regulator of programmed cell death. These findings reveal a role for MbIII in Myc biology, and establish that the oncogenic capacity of Myc is linked directly to its ability to temper the apoptotic response.
INTRODUCTION
The c-Myc oncogene encodes a helix-loop-helix (HLH) transcription factor that features prominently in the control of cell proliferation and in cancer. Capable of acting as both a transcriptional activator and repressor, Myc regulates many processes relevant to cell growth and proliferation (Grandori et al, 2000) . Consistent with its potent growth-promoting properties, Myc can also stimulate apoptosis (Evan et al, 1992) . Indeed, the ability of cells to undergo apoptosis in response to Myc is viewed as a major cellular defence against transformation by the Myc protein (Pelengaris et al, 2002) .
c-Myc is the defining member of a family of HLH transcription factors that have been conserved during vertebrate evolution (Grandori et al, 2000) . Within this family, the identification and analysis of highly conserved regions has been instrumental in understanding Myc function. The transcriptional activation domain of Myc, for example, contains two highly conserved regions, termed Myc boxes (Mb) I and II, that are important for Myc activity-MbI is a common site of mutations in cancer (Bhatia et al, 1994) and the target of Ras-mediated signalling (Sears et al, 2000) , whereas MbII contributes to activation of Myc target genes by recruitment of the coactivator transcription/ transformation domain-associated protein (TRRAP; McMahon et al, 1998) .
Recently, we found that a little-studied element within Myc-'Myc box III' (MbIII)-contributes to destruction of Myc by the proteasome (Herbst et al, 2004) . MbIII is centrally located within and is highly conserved among the c-, N-and s-Myc family members (supplementary Fig 1 online) . Curiously, despite its conservation, little is known about the role of MbIII in Myc activity. As MbI and II are implicated in both Myc destruction (Flinn et al, 1998) and function (e.g. Sarid et al, 1987) , we asked whether MbIII also participates in Myc's activity. Here, we present evidence that MbIII is important for Myc function and contributes to cellular transformation by downmodulating the ability of Myc to induce apoptosis.
RESULTS AND DISCUSSION
To understand how MbIII contributes to Myc function, we asked how the requirement for this element compares with that for highly conserved MbI and II in several aspects of Myc behaviour. We generated mutant Myc proteins in which we deleted MbI, MbII, or MbIII. We then compared these mutants in six measures of Myc activity: (i) anchorage-independent cell growth, (ii) alterations in cellular morphology, (iii) induction of S-phase, (iv) induction of apoptosis, (v) transcriptional regulation and (vi) ability to promote B-cell lymphomas in mice. The first five of these assays were performed with an inducible form of Myc that was generated by fusion to the hormone-binding domain of the oestrogen receptor (ER-Myc; Kim et al, 2003) ; we used ER-Myc to avoid potential secondary effects from constitutive overexpression of active Myc protein.
MbIII is important for transformation in vitro
Previous studies have demonstrated that the central region of Myc contributes to, but is not essential for, cellular transformation in vitro (Sarid et al, 1987; Stone et al, 1987) . To revisit the role of MbIII in this process, we asked whether deletion of this element alters the ability of Myc to drive anchorage-independent cell growth in Rat1a cells (Stone et al, 1987) . We activated the ERMyc fusion proteins (Fig 1A) in stably transduced Rat1a cells and measured colony formation in soft agar. As expected, ER-Myc wild type (WT) efficiently drove colony formation under these conditions (Fig 1B) . This activity was reduced modestly by deletion of MbI, and more severely by deletion of MbII. Curiously, deletion of MbIII had a significant effect on growth in soft agar, reducing the overall number of colonies by 60% and eliminating the very large colonies seen with the WT ER-Myc protein (Fig 1C) . This reduction in colony formation is consistent with earlier studies (Sarid et al, 1987; Stone et al, 1987) , and suggests that MbIII contributes to in vitro transformation by the Myc protein.
MbIII is dispensable for many aspects of Myc function
To understand why the DMbIII mutant is defective in transformation, we probed its activity in several assays. We first asked whether this protein could rescue morphological defects associated with deletion of the c-Myc gene. We expressed the ER-Myc fusion proteins (Fig 2A) in myc-null Ho15.19 cells (Mateyak et al, 1997) and scored their morphology. As reported (Mateyak et al, 1997) , WT Myc restored the fibroblast morphology of these cells, converting them from a flat, phase-dull, appearance (Fig 2, Vect. ) to a spindle-shaped, phase-bright, morphology (Fig 2B, WT) . Deletion of MbII blocked this activity. Interestingly, however, deletion of either MbI or III had little effect in this assay-both the DMbI and DMbIII mutants rescued the fibroblast appearance of these cells. The ability of these proteins to rescue Ho15.19 morphology demonstrates that MbI and III are dispensable for this activity, and reveals that the DMbI and DMbIII Myc mutants retain at least some aspect of WT Myc function.
To determine whether MbIII is important for the ability of Myc to stimulate S-phase entry (Eilers et al, 1989) , we activated ER-Myc proteins in serum-starved, density-arrested, Ho15.19 cells, and measured S-phase by bromodeoxyuridine (BrdU) incorporation (Fig 2C) . WT ER-Myc stimulated a significant level (12%) of QJ;S-phase entry in these cells. Consistent with previous reports (Spotts et al, 1997) , deletion of MbII disrupted this activity. Remarkably, both the DMbI and DMbIII mutants retained WT levels of S-phase-promoting activity. These results further support the idea that these proteins retain biological activity and demonstrate that the conserved MbI and III elements are required for only a subset of Myc functions.
MbIII is required for transcriptional repression
We next compared the contribution of MbI and III to transcriptional regulation. We generated clonal cell lines expressing either WT ER-Myc, or the DMbI or DMbIII mutants. We activated the ER-Myc fusion proteins, and measured transcript levels from four target genes that are activated by Myc (Fig 2D) , and four that are repressed ( Fig 2E) . As expected, activation of WT ER-Myc in these cells led to an induction of AHCY, Cad, Cdc2 and Rcl transcript levels. Comparison with the mutant proteins revealed that deletion of either MbI or III reduced (but did not eliminate) gene activation. The only exception to this trend was the Cdc2 gene, the induction of which was disrupted by deletion of either MbI or III. Thus, MbI and III seem to contribute to full transcriptional activation by Myc, but are not universally required for this process.
Analysis of Myc-repressed genes ( Fig 2E) revealed a very different pattern of behaviour. Deletion of MbI blocked transcriptional Myc box III is important for oncogenesis A. Herbst et al downregulation of the gadd45 and Gas1 genes, but had no effect on repression of p21 or p15. Deletion of MbIII, in contrast, eliminated transcriptional repression by Myc at all genes examined. On the basis of this result, we conclude that MbIII is essential for the ability of Myc to repress target gene transcription, whereas MbI is required for repression at only a subset of Myc target genes.
Deletion of MbIII promotes apoptosis by Myc
We next examined the ability of the ER-Myc fusion proteins to stimulate apoptosis. Stably transduced Ho15.19 cells were treated with increasing concentrations of the DNA-damaging drug etoposide, and cellular viability was determined. As expected, WT Myc stimulated cell death in response to etoposide (Fig 3A; compare 'WT' and 'Vect.'). Loss of MbI had little, if any, effect on the ability of Myc to induce apoptosis in this assay, whereas deletion of MbII completely disrupted this activity. Unexpectedly, deletion of MbIII significantly enhanced the ability of Myc to drive cell death: not only did the DMbIII deletion promote a higher rate of spontaneous apoptosis, but it also enhanced the efficiency of cell killing by etoposide by B8-fold. This result demonstrates that the proapoptotic activity of Myc can be enhanced by deletion of MbIII, and suggests that this element normally acts to attenuate the ability of Myc to induce apoptosis. To determine whether the enhanced ability of the DMbIII deletion mutant to stimulate apoptosis is responsible for the decreased transforming potential of this protein, we asked if we could rescue the transformation defect by blocking apoptosis. We ectopically expressed the antiapoptotic protein Bcl-2 (Vaux et al, 1988) , together with the Myc mutants, in Rat1a cells and repeated the transformation assay (Fig 3B) . Remarkably, Bcl-2 expression completely rescued the transformation defects associated with loss of MbIII. This effect was specific to the DMbIII deletion mutant, because defects associated with loss of MbI or II were not suppressed by Bcl-2 expression. These effects are unlikely to be due to secondary effects on the stability of Myc mutants, because Bcl-2 does not affect the rate of Myc proteolysis ( supplementary  Fig 2 online) . The ability to rescue the transformation defects of the DMbIII mutant by expression of Bcl-2 strongly suggests that Fig 3C) . This experiment confirmed that the DMbIII mutant has significantly enhanced proapoptotic activity in MEFs, despite being expressed at lower levels that the WT protein (Fig 3D) . Interestingly, both the DMbI and DMbII mutants showed increased proapoptotic activity in MEFs, compared with Ho15.19 cells. For DMbII, this could be accounted for by significantly higher levels of the mutant protein (Fig 3D, lane 7) . The DMbI mutant, however, was expressed at lower levels than WT Myc, suggesting that, like DMbIII, this mutant may have intrinsically higher apoptotic abilities. Note that treatment of cells with etoposide resulted in a marked reduction in the steady-state level of all Myc proteins (Fig 3D, even-numbered  lanes) , suggesting that Myc protein itself may be downregulated during the apoptotic programme.
To probe the mechanism through which the DMbIII mutant signals apoptosis, we examined activation of the Arf-p53 pathway in transduced MEFs (Fig 3D) . Although Arf levels were not altered significantly in this assay, p53 was potently induced by the presence of all Myc proteins (compare lanes 1 and 2 with lanes 3-10), and further induced by etoposide treatment. Importantly, all mutant Myc proteins induced p53 to a level comparable with that of WT Myc. These findings suggest that the enhanced proapoptotic function of the DMbI and III mutants is mediated by induction of a p53-independent pathway. 
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MbIII contributes to lymphomagenesis by Myc in vivo
To ask whether the function of MbIII is important for tumour development in vivo, we developed a system to study the effects of Myc overexpression within the haematopoietic compartment of mice (Fig 4A) . Haematopoietic stem cells (HSCs) were isolated from fetal livers of p53 þ /À mice and transduced with recombinant mouse stem-cell viruses (MSCVs) expressing various Myc proteins, together with the green fluorescent protein (GFP; Schmitt et al, 2000) . These modified p53 þ /À stem cells were then used to reconstitute the haematopoietic compartment of lethally irradiated recipient mice. Recipients were monitored for lymphoma development and dissemination by palpation of the lymph nodes, blood smears, and by whole-body fluorescent imaging of GFPexpressing tumour cells (Schmitt et al, 2002) . Mice transplanted with HSCs expressing WT Myc developed large disseminated GFP-positive lymphomas (Fig 4B) , with accompanying leukaemia, and were killed at morbidity at an average of 49.678.8 days after stem-cell transplantation (data not shown). This disease was completely penetrant in recipient animals, with no survival past 9 weeks (Fig 4C) . Immunophenotyping for both lymphoid and myeloid cell surface markers showed these tumours to be pre-B-cell lymphomas (B220 þ / IgMÀ; data not shown). Consistent with the requirement for MbII in all aspects of Myc activity, mice reconstituted with HSCs Myc box III is important for oncogenesis A. Herbst et al expressing the DMbII Myc mutant remained healthy and tumourfree throughout the course of the analysis (B200 days; Fig 4C) . Analysis of mice reconstituted with HSCs expressing the DMbI mutant revealed a very different pattern of tumour development. Unlike the large disseminated lymphomas seen in WT Myc recipients, DMbI recipients developed GFP þ leukaemia with minimal lymph node involvement (Fig 4B) . This tumour phenotype appeared with complete penetrance in recipient animals, but also correlated with a significantly longer overall survival time relative to WT Myc recipients (90.6712.2 days, Po0.0001; Fig 4C) . GFP imaging of DMbI recipients before killing showed an almost complete replacement of bone marrow with tumour cells. Curiously, staining for cell surface markers on these bone marrowderived tumour cells revealed the tumours to be of T-cell origin (B220À/Thy1 þ ; Fig 4B, lower panel) . Thus, deletion of MbI markedly alters the type of tumour initiated by Myc in this system, converting Myc from an inducer of B-cell lymphoma to an inducer of T-cell leukaemia.
Interestingly, analysis of mice reconstituted with HSCs expressing the DMbIII mutant showed a tumour phenotype that was significantly less severe than WT Myc recipients. Whereas tumorigenesis induced by WT Myc was completely penetrant, only 3 out of 7 recipients of DMbIII-infected HSCs developed pre-B-cell lymphomas (with accompanying leukaemia). Moreover, the DMbIII recipients that developed lymphomas showed a delayed onset of disease and prolonged survival (86.3716.3 days, Po0.001). Therefore, as we saw in vitro, MbIII has an important role in promoting transformation by Myc in vivo.
Finally, we repeated the in vivo analysis using HSCs that overexpressed Bcl-2 (Fig 4D) . This analysis gave a striking result: In the presence of overexpressed Bcl-2, mice reconstituted with HSCs expressing the WT, DMbI and DMbIII forms of Myc showed rapid, and similar, patterns of disease onset and progression. Tumorigenesis initiated by all three forms of Myc was completely penetrant, and all recipient mice were dead 50 days after reconstitution. The average survival of these three sets of mice was similar-32.773.7 days for WT, 35.374.1 days for DMbI (P ¼ 0.58) and 39.078.2 days for DMbIII (P ¼ 0.12). Crucially, all three sets of mice developed aggressive, highly disseminated, B-cell lymphomas (data not shown), revealing that blocking apoptosis can rescue not only the efficiency of tumorigenesis, but also the type of tumour, that is induced by the DMbI and DMbIII deletion mutants.
CONCLUSION
The data presented here demonstrate that the ability of Myc to attenuate its proapoptotic ability is important for regulating oncogenic transformation both in vitro and in vivo. Analysis in the mouse lymphomagenesis model reveals at least two ways in which modulation of the apoptotic response by Myc is important. For MbI, this function appears to regulate tumour type; the ability of Bcl-2 to switch the tumour type promoted by the DMbI mutant from T-cell leukaemia back to B-cell lymphoma is consistent with a model in which MbI downmodulates apoptosis specifically in B cells. For MbIII, this function regulates tumour penetrance and progression, consistent with a model in which MbIII functions broadly to attenuate Myc's apoptotic ability. As the DMbIII mutant retains many Myc activities, with the exception of transcriptional repression, we speculate that downmodulation of the apoptotic response may be related to repression of specific proapoptotic target genes. Regardless of the mechanism, however, these data establish that negative regulation of the apoptotic response is a process through which Myc promotes tumorigenesis and reveal that Myc can differentially regulate apoptosis in different cellular compartments. The anti-apoptotic function of MbIII underscores the complexity of cellular transformation by the Myc protein, and suggests a strategy for selectively inducing apoptosis in cancer cells by interfering with MbIII activity.
METHODS
Antibodies. Antibodies used in this study were: a-Myc N-262 (Santa Cruz, CA, USA), a-p53 (p53-505 NovoCastra, Newcastle upon Tyne, UK), a-p19ARF (ab14244 Abcam, Cambridge, MA, USA) and a-actin (AC-15 Sigma, St Louis, MO, USA). Plasmid DNA manipulations. WT and mutant Myc coding sequences (Herbst et al, 2004) were transferred into the retroviral vector pBabeHygroFER (Reilly & Herr, 2002) or into an MSCV retroviral vector upstream of IRES-GFP (Schmitt et al, 2002) . Mammalian cell culture. Rat1, Rat1a and Ho15.19 cells were transduced by retroviral gene transfer to express the appropriate pBabeHygroFER-Myc expression construct, or vector control. MEFs were retrovirally transduced with the appropriate MSC vector. Determination of S-phase in retrovirally transduced Ho15.19 cells was performed as described (Kim et al, 2003) . Analysis of cDNA levels for AHCY, Cad, Cdc2, Rcl, gadd45, gas1, p21 and p15 in clonal Rat1 cells expressing the appropriate ER-Myc proteins was performed as described (Kim et al, 2003) . All transformation and apoptosis assays have been performed a minimum of three times, with the exception of the MEF apoptosis assays-which have been independently performed twice, using different batches of MEFs. Determination of apoptosis. Retrovirally transduced Ho15.19 cells were seeded in six-well dishes (2 Â 10 5 cells per dish) in phenol red-free Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum (CS) and 2 mM 4 hydroxytamoxifen (4HT). After 24 h, cells were treated with increasing amounts of etoposide and incubated for a further 24 h. Adherent and nonadherent cells were collected, and cellular viability determined by trypan blue exclusion. Apoptosis assays in MEFs were performed similarly. Anchorage-independent growth. Retrovirally transduced Rat1a cells were seeded onto 6 cm dishes in soft agar supplemented with 2 mM 4HT. Cells were refed every 7 days. The number of colonies (4100 cells each) for each construct was determined 21 days after seeding, and normalized to the number of colonies for WT Myc. In vivo analysis of Myc mutants. Isolation, infection and transplantation of HSCs was performed as described (Schmitt et al, 2002) . HSCs were obtained from p53 þ /À C57BL/6 mouse (Jackson Laboratory, Bar Harbor, ME, USA) E13.5-15.5 fetal livers. Reconstituted animals were monitored for illness by lymph node palpation, by monitoring overall morbidity, and by whole-body fluorescence imaging (Schmitt et al, 2002) . The onset of lymph node hyperplasia was assessed by regular palpation of the axillary, brachial and inguinal lymph nodes. Overall survival was defined as the time from stem-cell reconstitution until the animal reached a terminal stage and had to be killed. Supplementary information is available at EMBO reports online (http://www.emboreports.org).
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